Site icon OncologyTube

Tumour biomarker changes after neoadjuvant chemotherapy in breast cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Sibylle Loibl, MD, PhD, from the German Breast Group, Neu-Isenburg, Germany, discusses changes in tumour expression of HER2 and hormone receptor status and pathological complete response (pCR) after neoadjuvant chemotherapy in a Japanese breast cancer registry.

European Medical Journal

Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews

Exit mobile version